Suchergebnisse - "rucaparib"

PubPharm (120)

1

PARP Inhibitors : Strategic Use and Optimal Management in Ovarian Cancer

enthalten in: Cancers | 2024

von Hirschl, N. | Leveque, W. | Granitto, J. | +3

2

Development of PARP inhibitors in advanced prostate cancer

enthalten in: Therapeutic advances in medical oncology | 2024

von Bourlon, M. | Valdez, P. | Castro, E.

3

Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations

enthalten in: The Annals of pharmacotherapy | 2023

von Pan, Y. | Hood, A. | Ahmad, H. | +1

4

A Real World Perspective of PARP Inhibitor Use in Gynecological Cancer Patients

enthalten in: Journal of pharmacy practice | 2023

von Lee, C. | Hernandez, J. | Liang, C. | +4

5

Hematological Toxicities with PARP Inhibitors in Prostate Cancer : A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials

enthalten in: Cancers | 2023

von Bowling, G. | Swargaloganathan, P. | Heintz, C. | +4

6

Safety of PARP inhibitors as maintenance therapy in ovarian cancer

enthalten in: Expert opinion on drug safety | 2023

von Cecere, S. | Casartelli, C. | Forte, M. | +2

7

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot : Development, Validation and Clinical Validation for Therapeutic Drug Monitoring

enthalten in: Pharmaceutics | 2023

von Canil, G. | Orleni, M. | Posocco, B. | +7

8

The effect of PARP inhibitors in homologous recombination proficient ovarian cancer : meta-analysis

enthalten in: Journal of chemotherapy (Florence, Italy) | 2023

von Skelin, M. | Šarčević, D. | Lešin Gaćina, D. | +3

9

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials

in: Cancers | 2023

von Gartrell C. Bowling | Piragash Swargaloganathan | Carly Heintz | +4

10

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring

in: Pharmaceutics | 2023

von Giovanni Canil | Marco Orleni | Bianca Posocco | +7

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]